Table 3.
Distribution of included studies based on study type, study design, time horizon, and analysis perspective
| Distribution based on | Number of studies (%) |
|---|---|
| Study type | 208 |
| Cost-effectiveness analysis | 30 (14%) |
| Cost-utility analysis | 166 (80%) |
| Both | 12 (6%) |
| Study design | 208 |
| Model based | 167 (80%) |
| Decision tree | 19 (9%) |
| Markov | 83 (40%) |
| Decision tree + Markov | 11 (5%) |
| Partitioned survival | 5 (2%) |
| Patient simulation | 30 (14%) |
| Others (micro costing, not described etc.) | 20 (10%) |
| Patient data based | 41 (20%) |
| RCT | 22 (11%) |
| Observational prospective | 9 (4%) |
| Observational retrospective | 8 (4%) |
| Others | 2 (1%) |
| Time horizon | 208 |
| Less than 1 year | 24 (12%) |
| 1–10 years | 78 (38%) |
| More than 10 years | 34 (16%) |
| Lifetime | 55 (26%) |
| Data not available | 17 (8%) |
| Perspective | 208 |
| Societal | 103 (50%) |
| Societal and payer | 41 (20%) |
| Societal and healthcare | 28 (13%) |
| Healthcare | 15 (7%) |
| Patient | 7 (3%) |
| Payer | 6 (3%) |
| Societal, healthcare, and payer | 4 (2%) |
| Hospital | 1 (0%) |
| Patient and payer | 1 (0%) |
| Payer and employer | 1 (0%) |
| Societal and patient | 1 (0%) |
RCT randomized controlled trial